Le Lézard
Classified in: Health, Science and technology
Subject: PDT

Elsevier Launches Entellecttm Platform, Unlocking Value by Creating AI-ready Life Sciences Data


NEW YORK, November 14, 2018 /PRNewswire/ --

Entellect leverages Elsevier's unique heritage to help enrich data and help companies overcome challenges in modern R&D 

Elsevier, the information analytics business specializing in science and health, today announced the launch of Entellect, a new cloud-based data platform designed to help life sciences companies overcome the challenges of modern R&D by enriching and harmonizing proprietary and external data and delivering it in an AI-ready environment.

     (Logo: https://mma.prnewswire.com/media/754760/Elsevier_Logo.jpg )

With nearly a fifth of pharmaceutical spending going to R&D and the average cost of bringing a new drug to market estimated at $4 billion USD, life sciences companies urgently need more efficient ways to analyze data. Drawing on its longstanding experience in the life sciences, Elsevier has created Entellect. This new platform can save time and costs by de-siloing, contextualizing and connecting drug, target, and disease data to deliver normalized, discoverable and model-ready information.

"The life sciences are perhaps the most demanding field in which to undertake data science," said Cameron Ross, Managing Director, Life Science Solutions, Elsevier. "The complexity involved is the reason so many companies are looking to AI, and machine and deep learning, to solve their biggest challenges. Too often their efforts are frustrated because of multiple data management barriers, and they're not yet seeing the insights from AI they expected.

"Entellect provides a sophisticated platform enabling them to get far more value out of their data. We designed Entellect to handle the sorts of data challenges that life sciences companies encounter - from handling huge volumes of existing data stored in individual Electronic Lab Notebooks, to finding the desired piece of information in scientific literature."

Entellect allows researchers to produce far more accurate predictive models across a range of pre- and post-market activities, including drug efficacy studies, risk-benefit analyses and pharmacovigilance activities. Some of the key attributes of Entellect include:

Entellect is already being used by Elsevier clients to gather, cleanse and connect more than 10,000 different unstructured medical documents in various formats to make them standardized and searchable. Entellect's taxonomy capabilities allow users to search across various fields including drug names, targets and diseases.

"At Elsevier we've spent decades creating solutions that allow individual researchers to find answers, and we've amassed a wealth of knowledge and practical experience in data science," said Tim Miller, VP Life Sciences Platform Solutions, Elsevier. "To develop Entellect, we took that data science knowledge and experience and applied it to prepare machine learning solutions.

"Entellect has been designed to radically simplify activities like text mining, data normalization, application of ontologies, mapping of ontologies onto multiple data sets - all techniques in which we have extensive experience."

Entellect is a smart and versatile life sciences platform that empowers R&D by leveraging Elsevier's trusted approach to data integration and harmonization. Entellect delivers connected and AI-ready data by linking and enriching disparate content against established life science taxonomies. Combined with the option of Elsevier data, the result is a scalable and customizable knowledge environment, enabling exploratory and predictive analytics applications.

For more information about Entellect, please visit www.elsevier.com/entellect

About Elsevier 

Elsevier is a global information analytics business that helps institutions and professionals advance healthcare, open science and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support and professional education, including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 38,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com

Media contact
Christopher Capot, Global Communications
Elsevier
+1-917-704-5174
[email protected]



These press releases may also interest you

at 21:51
On March 19, DMEGC Solar received the Acknowledgement of Manufacturer's Laboratory Competence issued by TÜV Rheinland, a global certification agency, proving its excellence in PV module R&D and quality control. The acknowledgement is TÜV Rheinland's...

at 21:45
Shop TJC Ltd. (TJC) is thrilled to announce the successful completion of its third collaboration with the iconic BBC...

at 21:32
Arctech has recently signed a contract for the 500MW Manah I power plant project in Oman, following its successful bid for the 588MW Manah II PV project in Oman earlier in 2023. This consecutive project win showcases Arctech's customized solutions...

at 21:15
Techtouch, Inc. (Headquarter: Tokyo, Japan, President/CEO: Naka Imuta) announced today that it ranked 8th in the 21st Technology Fast 50 Japan, with three-year revenue growth of 468.6%. Technology Fast 50 Japan, held annually by Deloitte Tohmatsu...

at 21:00
OKX Ventures, the investment arm of leading crypto exchange and Web3 technology company OKX, today published a report titled 'Unlocking the Infinite Potential of Crypto and AI.' The report explores the convergence of AI and crypto, a major trend in...

at 21:00
The "Strategic Storytelling for Internal Communications: Using the Power of Storytelling to Engage Employees, Manage Organizational Change, and Shape Workplace Cultures" conference has been added to  ResearchAndMarkets.com's offering. The Best...



News published on and distributed by: